LEGN Legend Biotech
- 44.380
- +1.410+3.28%
- 44.380
- 0.0000.00%
Legend Biotech News
Legend Biotech Price Target Raised to $86.00/Share From $85.00 by RBC Capital
Legend Biotech Price Target Raised to $86.00/Share From $85.00 by RBC Capital
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Green Thumb Industries (OtherGTBIF) and OmniAb (OABI)
Legend Biotech's Loss Narrows in Q1 as Revenue Surges
Genscript Biotech's (HKG:1548) Nasdaq-listed subsidiary Legend Biotech reported a loss of $59.8 million, or $0.16 per share, in the first quarter, down from $112.1 million, or $0.34 per share, a year
Scotiabank Sticks to Their Buy Rating for Legend Biotech (LEGN)
Buy Rating for Legend Biotech Anchored by Carvykti's Growth and Market Penetration Potential
Legend Biotech Is Maintained at Buy by HC Wainwright & Co.
Legend Biotech Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Legend Biotech, Lowers Price Target to $86
HC Wainwright & Co. analyst Mitchell Kapoor maintains Legend Biotech (NASDAQ:LEGN) with a Buy and lowers the price target from $87 to $86.
Legend Biotech Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 100.93% HC Wainwright & Co. $87 → $86 Maintains Buy 05/09/2024 103.27% HC Wainwright & Co. → $8
RBC Adjusts Price Target on Legend Biotech to $86 From $85 on Model Updates, Maintains Outperform Rating
Legend Biotech (LEGN) has an average outperform rating and a price target range of $65 to $95, according to analysts polled by Capital IQ.
Analysts Are Bullish on Top Healthcare Stocks: Legend Biotech (LEGN), Oculis Holding (OCS)
Legend Biotech Corp (LEGN) Q1 2024 Earnings Call Transcript Highlights: Soaring CARVYKTI Sales ...
Earnings Call Summary | Legend Biotech(LEGN.US) Q1 2024 Earnings Conference
The following is a summary of the Legend Biotech Corporation (LEGN) Q1 2024 Earnings Call Transcript:Financial Performance:Legend Biotech reported net trade sales of $157 million for the first quarter
Buy Rating Affirmed for Legend Biotech on CARVYKTI Growth and Positive Clinical Developments
William Blair Remains a Hold on Legend Biotech (LEGN)
Legend Biotech Vaults on Quarterlies
Sector Update: Health Care Stocks Decline Pre-Bell Monday
Health care stocks were declining pre-bell Monday, with the Health Care Select Sector SPDR Fund (XLV) slightly lower and iShares Biotechnology ETF (IBB) was recently down 0.3%. Legend Biotech (LEGN) w
Sector Update: Health Care
Health care stocks were steady pre-bell Monday, with the Health Care Select Sector SPDR Fund (XLV) and iShares Biotechnology ETF (IBB) both inactive. Legend Biotech (LEGN) stock was up more than 7% af
Legend Biotech's Strong Q1 Growth and Strategic Expansion
Kingsley Biotechnology (01548.HK): Legendary Biotech's total revenue in the first quarter was 93.991 million US dollars, up 158.67% year-on-year
Kingsley Biotech (01548.HK) announced Legendary Biotech's results for the first quarter of 2024, with total revenue of US$93.91 million, up 158.67% year on year; ordinary equity holders of the parent company should have accounted for a loss of US$597.93 million, a year-on-year narrowing of 46.66%; loss per share was US$0.16.
Kingsley Biotechnology (01548): Legendary Biotech's total revenue in the first quarter was 93.991 million US dollars, up 158.67% year-on-year
Kingsley Biotech (01548) announced Legendary Biotech's results for the first quarter of 2024, with total revenue of US$93.91 million, an increase of 158.67%; ordinary equity holders of the parent company should have accounted for a loss of US$597.93 million, a year-on-year narrowing of 46.66%; and a loss of US$0.16 per share.
Analysis
Price Target
No Data
